We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PsychoGenics Announces Drug Discovery Agreement with Cephalon
News

PsychoGenics Announces Drug Discovery Agreement with Cephalon

PsychoGenics Announces Drug Discovery Agreement with Cephalon
News

PsychoGenics Announces Drug Discovery Agreement with Cephalon

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PsychoGenics Announces Drug Discovery Agreement with Cephalon"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PsychoGenics Inc. has announced that it has entered into a drug discovery agreement with Cephalon, Inc. The agreement provides that Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies.

PsychoGenics and Cephalon aim to jointly identify drug candidates suitable for clinical development. If Cephalon undertakes further development of the clinical candidates, PsychoGenics will receive milestone payments as well as royalties. If PsychoGenics undertakes further development, it will make milestone and royalty payments to Cephalon.

Dr. Emer Leahy, President and CEO of PsychoGenics, said, "We are delighted to partner with Cephalon and look forward to a successful collaboration. We are confident that combining Cephalon’s and PsychoGenics’ complementary strengths and expertise will enable us to identify a new generation of treatments for neuropsychiatric disorders.”

PsychoGenics’ technologies combine its broad in vivo behavioral expertise together with recent developments in robotics, computer vision and bio/cheminformatics to evaluate drug candidates for potential therapeutic utility across the spectrum of neuropsychiatric disease indications.

Advertisement